The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair

Volume: 190, Pages: 114616 - 114616
Published: Aug 1, 2021
Abstract
Anthracycline are inhibitors of topoisomerase II leading to DNA double strand breaks, and it is widely used for treatment of breast cancer. eIF3a is the largest subunit of eukaryotic translation initiation factor 3 (eIF3) and highly expressed in breast cancer. In this study, we investigated the role of eIF3a in DSB DNA repair and the response of breast cancer patients to anthracycline-based chemotherapy.MTT assay was used to detect anthracycline...
Paper Details
Title
The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair
Published Date
Aug 1, 2021
Volume
190
Pages
114616 - 114616
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.